| Year |
Citation |
Score |
| 2023 |
Park Y, Lelo A, Harris B, Berry DL, Chaldekas K, Kim JS, Waldman T. Identification of STAG2-Mutant Bladder Cancers by Immunohistochemistry. Methods in Molecular Biology (Clifton, N.J.). 2684: 145-151. PMID 37410232 DOI: 10.1007/978-1-0716-3291-8_8 |
0.312 |
|
| 2022 |
Kwon J, Choi H, Ware AD, Morillo BC, Wang H, Bouker KB, Lu X, Waldman T, Han C. USP13 promotes development and metastasis of high-grade serous ovarian carcinoma in a novel mouse model. Oncogene. PMID 35173307 DOI: 10.1038/s41388-022-02224-x |
0.332 |
|
| 2021 |
Boddu PC, Gupta AK, Kim JS, Neugebauer KM, Waldman T, Pillai MM. Generation of scalable cancer models by combining AAV-intron-trap, CRISPR/Cas9, and inducible Cre-recombinase. Communications Biology. 4: 1184. PMID 34645977 DOI: 10.1038/s42003-021-02690-1 |
0.352 |
|
| 2020 |
He X, Kim JS, Diaz-Martinez L, Han C, Lane WS, Budnik B, Waldman T. USP13 interacts with cohesin and regulates its ubiquitination in human cells. The Journal of Biological Chemistry. PMID 33334891 DOI: 10.1074/jbc.RA120.015762 |
0.344 |
|
| 2020 |
Waldman T. Emerging themes in cohesin cancer biology Nature Reviews Cancer. 20: 504-515. PMID 32514055 DOI: 10.1038/S41568-020-0270-1 |
0.458 |
|
| 2019 |
Kim JS, He X, Liu J, Duan Z, Kim T, Gerard J, Kim B, Pillai MM, Lane WS, Noble WS, Budnik B, Waldman T. Systematic proteomics of endogenous human cohesin reveals an interaction with diverse splicing factors and RNA binding proteins required for mitotic progression. The Journal of Biological Chemistry. PMID 31010829 DOI: 10.1074/Jbc.Ra119.007832 |
0.407 |
|
| 2018 |
Lelo A, Prip F, Harris BT, Solomon D, Berry DL, Chaldekas K, Kumar A, Simko J, Jensen JB, Bhattacharyya P, Mannion C, Kim JS, Philips G, Dyrskjøt L, Waldman T. STAG2 Is a Biomarker for Prediction of Recurrence and Progression in Papillary Non-Muscle-Invasive Bladder Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29954776 DOI: 10.1158/1078-0432.Ccr-17-3244 |
0.386 |
|
| 2018 |
Lelo A, Harris BT, Berry DL, Chaldekas K, Kumar A, Solomon D, Simko J, Bhattacharyya P, Mannion C, Kim J, Philips G, Waldman T. Abstract 1558: STAG2 as a biomarker for prediction of recurrence in papillary non-muscle invasive bladder cancer Cancer Research. 78: 1558-1558. DOI: 10.1158/1538-7445.Am2018-1558 |
0.422 |
|
| 2017 |
Petronczki MP, van der Lelij P, Lieb S, Jude J, Wutz G, Santos CP, Falkenberg K, Schlattl A, Ban J, Schwentner R, Hoffmann T, Kovar H, Real FX, Waldman T, Pearson MA, et al. Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts. Elife. 6. PMID 28691904 DOI: 10.7554/Elife.26980 |
0.504 |
|
| 2017 |
Hill VK, Kim JS, James CD, Waldman T. Correction of PTEN mutations in glioblastoma cell lines via AAV-mediated gene editing. Plos One. 12: e0176683. PMID 28464039 DOI: 10.1371/Journal.Pone.0176683 |
0.575 |
|
| 2017 |
Lelij Pvd, Lieb S, Jude J, Wutz G, Santos CP, Falkenberg K, Schlattl A, Ban J, Schwentner R, Hoffmann T, Kovar H, Real FX, Waldman T, Pearson MA, Kraut N, et al. Author response: Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts Elife. DOI: 10.7554/Elife.26980.026 |
0.324 |
|
| 2017 |
Lelij PVD, Lieb S, Jude J, Wutz G, Pereira C, Falkenberg K, Ban J, Kovar H, Waldman T, Real F, Pearson M, Kraut N, Peters J, Zuber J, Petronczki MP. Abstract 3452: The cohesin subunitSTAG1is a hardwired genetic dependency ofSTAG2mutant cancer cells Cancer Research. 77: 3452-3452. DOI: 10.1158/1538-7445.Am2017-3452 |
0.53 |
|
| 2016 |
Waldman T. The Inaugural Use of Gene Editing for the Study of Tumor Suppressor Pathways in Human Cells—p21WAF1/CIP1 Cancer Research. 76: 4598-4601. PMID 27528579 DOI: 10.1158/0008-5472.Can-16-1972 |
0.455 |
|
| 2016 |
Hashizume R, Zhang A, Mueller S, Prados MD, Lulla RR, Goldman S, Saratsis AM, Mazar AP, Stegh AH, Cheng SY, Horbinski C, Haas-Kogan DA, Sarkaria JN, Waldman T, James CD. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro-Oncology. PMID 27370397 DOI: 10.1093/Neuonc/Now106 |
0.308 |
|
| 2016 |
Hill VK, Kim JS, Waldman T. Cohesin mutations in human cancer. Biochimica Et Biophysica Acta. PMID 27207471 DOI: 10.1016/J.Bbcan.2016.05.002 |
0.5 |
|
| 2016 |
Kim JS, He X, Orr B, Wutz G, Hill V, Peters JM, Compton DA, Waldman T. Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring Tumor-Derived Mutations in STAG2. Plos Genetics. 12: e1005865. PMID 26871722 DOI: 10.1371/Journal.Pgen.1005865 |
0.477 |
|
| 2015 |
Walia V, Prickett T, Kim J, Gartner JJ, Lin JC, Rosenberg SA, Elble RC, Solomon DA, Waldman T, Samuels Y. Abstract LB-065: Mutational and functional analysis of the tumor suppressor PTPRD in human melanoma Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-065 |
0.412 |
|
| 2015 |
Lu Y, Chang Y, Cheng L, Wei K, Ozawa T, Kim J, Waldman T, James CD. MTR-07GLIOBLASTOMA ADAPTATION TO SUSTAINED cdk4/6 INHIBITION INVOLVES SUPPRESSION OF Rb EXPRESSION THROUGH HISTONE H3K4 MODIFICATION Neuro-Oncology. 17: v125.3-v125. DOI: 10.1093/Neuonc/Nov219.07 |
0.358 |
|
| 2015 |
Ander N, Lerner R, Huang X, Tom M, Ngo V, Solomon D, Mueller S, Paris P, Zhang Z, Gupta N, Waldman T, Goldman S, James D, Hashizume R. Bt-03Targeted Inhbition Of Histone Demethylase Activity For The Treatment Of Pediatric Brainstem Gliomas Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov061.13 |
0.423 |
|
| 2014 |
Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, Fang D, Huang X, Tom MW, Ngo V, Solomon D, Mueller S, Paris PL, Zhang Z, Petritsch C, ... ... Waldman TA, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nature Medicine. 20: 1394-6. PMID 25401693 DOI: 10.1038/Nm.3716 |
0.347 |
|
| 2014 |
Walia V, Prickett TD, Kim JS, Gartner JJ, Lin JC, Zhou M, Rosenberg SA, Elble RC, Solomon DA, Waldman T, Samuels Y. Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma. Human Mutation. 35: 1301-10. PMID 25113440 DOI: 10.1002/Humu.22630 |
0.494 |
|
| 2014 |
Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, Patidar R, Hurd L, Chen L, Shern JF, Liao H, Wen X, Gerard J, Kim JS, Lopez Guerrero JA, ... ... Waldman T, et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. Plos Genetics. 10: e1004475. PMID 25010205 DOI: 10.1371/Journal.Pgen.1004475 |
0.434 |
|
| 2014 |
Solomon DA, Kim JS, Waldman T. Cohesin gene mutations in tumorigenesis: from discovery to clinical significance. Bmb Reports. 47: 299-310. PMID 24856830 DOI: 10.5483/Bmbrep.2014.47.6.092 |
0.488 |
|
| 2014 |
Bailey ML, O'Neil NJ, van Pel DM, Solomon DA, Waldman T, Hieter P. Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition. Molecular Cancer Therapeutics. 13: 724-32. PMID 24356817 DOI: 10.1158/1535-7163.Mct-13-0749 |
0.453 |
|
| 2014 |
Solomon DA, Kim J, Bondaruk J, Shariat SF, Wang Z, Elkahloun A, Gerard J, Zhuang D, Zhang S, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Kuefer R, Netto GJ, ... ... Waldman T, et al. Frequent truncating mutations of the cohesin complex gene STAG2 in urothelial carcinoma of the bladder. Journal of Clinical Oncology. 32: 290-290. DOI: 10.1200/Jco.2014.32.4_Suppl.290 |
0.441 |
|
| 2013 |
Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, ... ... Waldman T, et al. Frequent truncating mutations of STAG2 in bladder cancer. Nature Genetics. 45: 1428-30. PMID 24121789 DOI: 10.1038/Ng.2800 |
0.471 |
|
| 2013 |
Vartanian S, Bentley C, Brauer MJ, Li L, Shirasawa S, Sasazuki T, Kim JS, Haverty P, Stawiski E, Modrusan Z, Waldman T, Stokoe D. Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines. The Journal of Biological Chemistry. 288: 2403-13. PMID 23188824 DOI: 10.1074/Jbc.M112.394130 |
0.374 |
|
| 2012 |
Cen L, Carlson BL, Schroeder MA, Ostrem JL, Kitange GJ, Mladek AC, Fink SR, Decker PA, Wu W, Kim JS, Waldman T, Jenkins RB, Sarkaria JN. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro-Oncology. 14: 870-81. PMID 22711607 DOI: 10.1093/Neuonc/Nos114 |
0.354 |
|
| 2012 |
Huillard E, Hashizume R, Phillips JJ, Griveau A, Ihrie RA, Aoki Y, Nicolaides T, Perry A, Waldman T, McMahon M, Weiss WA, Petritsch C, James CD, Rowitch DH. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proceedings of the National Academy of Sciences of the United States of America. 109: 8710-5. PMID 22586120 DOI: 10.1073/Pnas.1117255109 |
0.386 |
|
| 2012 |
Solomon D, Kim T, Diaz-Martinez L, Fair J, Elkahloun A, Harris B, Toretsky J, Rosenberg S, Shukla N, Ladanyi M, Samuels Y, James CD, Yu H, Kim J, Waldman T. Abstract 3114: Mutational inactivation of STAG2 causes aneuploidy in human cancer Cancer Research. 72: 3114-3114. DOI: 10.1158/1538-7445.Am2012-3114 |
0.44 |
|
| 2011 |
Nicolaides TP, Li H, Solomon DA, Hariono S, Hashizume R, Barkovich K, Baker SJ, Paugh BS, Jones C, Forshew T, Hindley GF, Hodgson JG, Kim JS, Rowitch DH, Weiss WA, ... Waldman TA, et al. Targeted therapy for BRAFV600E malignant astrocytoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 7595-604. PMID 22038996 DOI: 10.1158/1078-0432.Ccr-11-1456 |
0.432 |
|
| 2011 |
Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahloun AG, Harris BT, Toretsky JA, Rosenberg SA, Shukla N, Ladanyi M, Samuels Y, James CD, Yu H, Kim JS, Waldman T. Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (New York, N.Y.). 333: 1039-43. PMID 21852505 DOI: 10.1126/Science.1203619 |
0.527 |
|
| 2011 |
Nguyen QD, Perumal M, Waldman TA, Aboagye EO. Glucose metabolism measured by [¹⁸F]fluorodeoxyglucose positron emission tomography is independent of PTEN/AKT status in human colon carcinoma cells. Translational Oncology. 4: 241-8. PMID 21804920 DOI: 10.1593/Tlo.11118 |
0.366 |
|
| 2011 |
Kim JS, Xu X, Li H, Solomon D, Lane WS, Jin T, Waldman T. Mechanistic analysis of a DNA damage-induced, PTEN-dependent size checkpoint in human cells. Molecular and Cellular Biology. 31: 2756-71. PMID 21536651 DOI: 10.1128/Mcb.01323-10 |
0.421 |
|
| 2011 |
Li HF, Keeton A, Vitolo M, Maddox C, Rasmussen L, Hobrath J, White EL, Park BH, Piazza GA, Kim JS, Waldman T. A high-throughput screen with isogenic PTEN+/+ and PTEN-/- cells identifies CID1340132 as a novel compound that induces apoptosis in PTEN and PIK3CA mutant human cancer cells. Journal of Biomolecular Screening. 16: 383-93. PMID 21335596 DOI: 10.1177/1087057110397357 |
0.521 |
|
| 2010 |
Duncan CG, Killela PJ, Payne CA, Lampson B, Chen WC, Liu J, Solomon D, Waldman T, Towers AJ, Gregory SG, McDonald KL, McLendon RE, Bigner DD, Yan H. Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget. 1: 265-77. PMID 21113414 DOI: 10.18632/Oncotarget.137 |
0.453 |
|
| 2010 |
Lopez GY, Reitman ZJ, Solomon D, Waldman T, Bigner DD, McLendon RE, Rosenberg SA, Samuels Y, Yan H. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochemical and Biophysical Research Communications. 398: 585-7. PMID 20603105 DOI: 10.1016/J.Bbrc.2010.06.125 |
0.381 |
|
| 2010 |
Michaud K, Solomon DA, Oermann E, Kim JS, Zhong WZ, Prados MD, Ozawa T, James CD, Waldman T. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Research. 70: 3228-38. PMID 20354191 DOI: 10.1158/0008-5472.Can-09-4559 |
0.32 |
|
| 2009 |
Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ, Ashworth A. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. Embo Molecular Medicine. 1: 315-22. PMID 20049735 DOI: 10.1002/Emmm.200900041 |
0.486 |
|
| 2009 |
Vitolo MI, Weiss MB, Szmacinski M, Tahir K, Waldman T, Park BH, Martin SS, Weber DJ, Bachman KE. Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells. Cancer Research. 69: 8275-83. PMID 19843859 DOI: 10.1158/0008-5472.Can-09-1067 |
0.501 |
|
| 2009 |
Li H, Kim J, Waldman T. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells Radiation Oncology. 4: 43-43. PMID 19828040 DOI: 10.1186/1748-717X-4-43 |
0.397 |
|
| 2009 |
Solomon DA, Kim JS, Ressom HW, Sibenaller Z, Ryken T, Jean W, Bigner D, Yan H, Waldman T. Sample type bias in the analysis of cancer genomes. Cancer Research. 69: 5630-3. PMID 19567670 DOI: 10.1158/0008-5472.Can-09-1055 |
0.418 |
|
| 2009 |
Solomon DA, Kim JS, Yang XR, Tucker MA, Goldstein AM, Samuels Y, Waldman T. Lack of inherited mutations of PTPRD in familial melanoma and melanoma-astrocytoma syndrome. Pigment Cell & Melanoma Research. 22: 489-91. PMID 19500277 DOI: 10.1111/J.1755-148X.2009.00587.X |
0.372 |
|
| 2009 |
Gabai VL, Yaglom JA, Waldman T, Sherman MY. Heat Shock Protein Hsp72 Controls Oncogene-Induced Senescence Pathways in Cancer Cells Molecular and Cellular Biology. 29: 559-569. PMID 19001088 DOI: 10.1128/Mcb.01041-08 |
0.469 |
|
| 2008 |
Solomon DA, Kim JS, Cronin JC, Sibenaller Z, Ryken T, Rosenberg SA, Ressom H, Jean W, Bigner D, Yan H, Samuels Y, Waldman T. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. Cancer Research. 68: 10300-6. PMID 19074898 DOI: 10.1158/0008-5472.Can-08-3272 |
0.477 |
|
| 2008 |
Solomon DA, Kim JS, Jean W, Waldman T. Conspirators in a capital crime: co-deletion of p18INK4c and p16INK4a/p14ARF/p15INK4b in glioblastoma multiforme. Cancer Research. 68: 8657-60. PMID 18974105 DOI: 10.1158/0008-5472.Can-08-2084 |
0.42 |
|
| 2008 |
Kim JS, Bonifant C, Bunz F, Lane WS, Waldman T. Epitope tagging of endogenous genes in diverse human cell lines. Nucleic Acids Research. 36: e127. PMID 18784188 DOI: 10.1093/Nar/Gkn566 |
0.721 |
|
| 2008 |
Solomon DA, Kim JS, Jenkins S, Ressom H, Huang M, Coppa N, Mabanta L, Bigner D, Yan H, Jean W, Waldman T. Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme. Cancer Research. 68: 2564-9. PMID 18381405 DOI: 10.1158/0008-5472.Can-07-6388 |
0.422 |
|
| 2007 |
Bonifant CL, Kim JS, Waldman T. NHERFs, NEP, MAGUKs, and more: interactions that regulate PTEN. Journal of Cellular Biochemistry. 102: 878-85. PMID 17786934 DOI: 10.1002/Jcb.21518 |
0.697 |
|
| 2007 |
Lee C, Kim J, Waldman T. Activated PI3K signaling as an endogenous inducer of p53 in human cancer. Cell Cycle. 6: 394-396. PMID 17329971 DOI: 10.4161/Cc.6.4.3810 |
0.484 |
|
| 2007 |
Kim JS, Lee C, Bonifant CL, Ressom H, Waldman T. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA. Molecular and Cellular Biology. 27: 662-77. PMID 17060456 DOI: 10.1128/Mcb.00537-06 |
0.724 |
|
| 2006 |
Stein U, Arlt F, Walther W, Smith J, Waldman T, Harris ED, Mertins SD, Heizmann CW, Allard D, Birchmeier W, Schlag PM, Shoemaker RH. The Metastasis-Associated Gene S100A4 Is a Novel Target of β-catenin/T-cell Factor Signaling in Colon Cancer Gastroenterology. 131: 1486-1500. PMID 17101323 DOI: 10.1053/J.Gastro.2006.08.041 |
0.392 |
|
| 2005 |
Bonifant CL, Waldman T. 'Cables' suspends cancer in mice. Cancer Biology & Therapy. 4: 864-5. PMID 16123580 DOI: 10.4161/Cbt.4.8.2012 |
0.662 |
|
| 2004 |
Samuels Y, Waldman T. Oncogenic Mutations of PIK3CA in Human Cancers Current Topics in Microbiology and Immunology. 347: 21-41. PMID 20535651 DOI: 10.1007/82_2010_68 |
0.505 |
|
| 2004 |
Lee C, Kim J, Waldman T. PTEN Gene Targeting Reveals a Radiation-Induced Size Checkpoint in Human Cancer Cells Cancer Research. 64: 6906-6914. PMID 15466180 DOI: 10.1158/0008-5472.Can-04-1767 |
0.461 |
|
| 2004 |
Nishanian TG, Waldman T. Interaction of the BMPR-IA tumor suppressor with a developmentally relevant splicing factor. Biochemical and Biophysical Research Communications. 323: 91-7. PMID 15351706 DOI: 10.1016/J.Bbrc.2004.08.060 |
0.725 |
|
| 2004 |
Nishanian TG, Kim JS, Foxworth A, Waldman T. Suppression of tumorigenesis and activation of Wnt signaling by bone morphogenetic protein 4 in human cancer cells. Cancer Biology & Therapy. 3: 667-75. PMID 15197354 DOI: 10.4161/Cbt.3.7.965 |
0.76 |
|
| 2004 |
Kim J, Lee C, Foxworth A, Waldman T. B-Raf is dispensable for K-Ras-mediated oncogenesis in human cancer cells. Cancer Research. 64: 1932-1937. PMID 15026326 DOI: 10.1158/0008-5472.Can-03-3862 |
0.353 |
|
| 2004 |
Waldman TA. Gene targeting in cultured human cells. Methods in Molecular Biology (Clifton, N.J.). 241: 163-74. PMID 14970652 DOI: 10.1385/1-59259-646-0:163 |
0.43 |
|
| 2003 |
Waldman T, Lee C, Nishanian TG, Kim JS. Human somatic cell gene targeting. Current Protocols in Molecular Biology / Edited by Frederick M. Ausubel ... [Et Al.]. Unit 9.15. PMID 18265333 DOI: 10.1002/0471142727.Mb0915S62 |
0.742 |
|
| 2003 |
Xie Z, Zeng X, Waldman T, Glazer RI. Transformation of mammary epithelial cells by 3-phosphoinositide- dependent protein kinase-1 activates beta-catenin and c-Myc, and down-regulates caveolin-1. Cancer Research. 63: 5370-5. PMID 14500370 |
0.356 |
|
| 2003 |
Kim JS, Crooks H, Foxworth A, Waldman T. Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors. Molecular Cancer Therapeutics. 1: 1355-9. PMID 12516970 |
0.353 |
|
| 2003 |
Lee C, Waldman T. Human somatic cell knockouts reveal determinants of sensitivity and resistance to proteasome inhibitor PS-341. Cancer Biology & Therapy. 2: 700-701. DOI: 10.4161/Cbt.2.6.574 |
0.421 |
|
| 2002 |
Kim JS, Crooks H, Dracheva T, Nishanian TG, Singh B, Jen J, Waldman T. Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. Cancer Research. 62: 2744-8. PMID 12019147 |
0.766 |
|
| 1999 |
Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. The Journal of Clinical Investigation. 104: 263-9. PMID 10430607 DOI: 10.1172/Jci6863 |
0.414 |
|
| 1998 |
Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science (New York, N.Y.). 282: 1497-501. PMID 9822382 DOI: 10.1126/Science.282.5393.1497 |
0.329 |
|
| 1997 |
Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler K, Vogelstein B, Williams J. Cell-cycle arrest versus cell death in cancer therapy. Nature Medicine. 3: 1034-6. PMID 9288734 DOI: 10.1038/Nm0997-1034 |
0.442 |
|
| 1996 |
Polyak K, Waldman T, He TC, Kinzler KW, Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes & Development. 10: 1945-52. PMID 8756351 DOI: 10.1101/Gad.10.15.1945 |
0.367 |
|
| 1996 |
Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 381: 713-6. PMID 8649519 DOI: 10.1038/381713A0 |
0.364 |
|
| 1995 |
Tokino T, Thiagalingam S, el-Deiry WS, Waldman T, Kinzler KW, Vogelstein B. p53 tagged sites from human genomic DNA. Human Molecular Genetics. 3: 1537-42. PMID 7833908 DOI: 10.1093/Hmg/3.9.1537 |
0.355 |
|
| Show low-probability matches. |